Papatheodoridi M. Rates and predictors of HBsAg loss after discontinuation of effective long-term Entecavir or Tenofovir therapy in non-cirrhotic HBeAg-negative Chronic Hepatitis B patients: Results from the DARING-B prospective Greek study. PS-159.
AQ-13 veelbelovend medicijn tegen resistente ‘Plasmodium falciparum’
sep 2017 | Parasitaire infecties